Drugs / LY4006896
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06809400 | Feb 2025 → Jan 2028 expected | Parkinson disease | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4006896 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06809400 ↗ |
| Route | Intravenous | “Administered intravenously (IV)” NCT06809400 ↗ |